Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: dalroi who wrote (4625)	9/10/2001 10:41:00 AM
From: Biomaven	Read Replies (1) \| Respond to of 52153

Here's some PR from Harry Tracy's Neuroinvestment. For those not familiar with this newsletter, it's one of the few good biotech newsletters that I know. The entire latest issue (thanks to MZ for pointing this out to me) is available on the Cortex website cortexpharm.com - I assume this is intentional, but enjoy it while it's there in case it isn't. <g> Monday September 10, 9:00 am Eastern Time Press Release SOURCE: NeuroInvestment Memory Drug Programs Reviewed By NeuroInvestment RYE, NH--(INTERNET WIRE)--Sep 10, 2001-- NeuroInvestment has released its report covering research focused upon therapeutics for Mild Cognitive Impairment (MCI) and other age-related memory disorders. These disorders do not have the devastating impact of dementia, which constitutes a separate area to be addressed in an upcoming review, but they significantly detract from the level of functioning and quality of life for millions. This category has just started to be appreciated in terms of its prevalence and impact. The FDA has recently acknowledged that MCI is a diagnostic entity unto itself, and a valid target for drug intervention. MCI already affects four to five million Americans, and is going to become increasingly salient as the populations of the US, Europe, and Japan age. Adding in the vast and still ambiguously defined group suffering from Age Associated Memory Impairment (AAMI), those for whom misplaced keys and forgotten names have become more than just a transient annoyance, we calculate that the total prevalence in the US alone is now between fifteen and twenty million individuals. This is a market that will be driven by the determination of 'boomers' to maintain the vigor of youth as long as possible, including the vitality of their intellect. Memory disorders thus constitute one of the largest categories of CNS disorders, a category that is completely unaddressed other than via unproven herbal remedies. It is one of the greatest untapped opportunities for pharmaceutical development. The companies whose programs are reviewed include: Axonyx (NASDAQ:AXYX - news), Cortex (AMEX:COR - news), David Pharma, Helicon Therapeutics, Memory Pharmaceuticals, NeuroLogic, MitoKor, Drug Abuse Sciences, Neurogen (NASDAQ:NRGN - news), NeoTherapeutics (NASDAQ:NEOT - news), and Sention. Cortex Pharmaceuticals, whose Ampakine platform has more human data regarding its memory benefits than any other, is given a comprehensive corporate review. Recent and pending issues of NeuroInvestment include: August 2001: Overview of the Forty Best Private CNS Companies September 2001: Mild Cognitive Impairment October 2001: Alzheimer's Dementia NeuroInvestment has set the standard for reviews of the CNS pharmaceutical industry since 1995, and is the leading publisher of independent research information regarding companies specializing in the development of therapeutics for neurological/psychiatric disorders. NeuroInvestment is published monthly. Hardcopy and/or electronic delivery available. Subscription Rates: 3-month trial $130, Individual:1 year $420, 2 year $720. Corporate/Institutional: 3-month trial $190, 1 year $690, 2 years $1180. Outside the US/Canada add $30 per year for hardcopy airmail. Contact: NeuroInvestment, P.O. Box 458, Rye, NH 03870; 603-964-9640; fax: 603-964-7561 E-mail: neuroinv@neuroinv.com. Web Site: www.neuroinvestment.com. ------------------------------------------------ Contact: Dr. Harry M. Tracy NeuroInvestment 603-964-9640